Top-Rated StocksTop-RatedNASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis → Executive Order To Wipe Out Your Bank Accounts (From Oasis Gold) (Ad) Free MRUS Stock Alerts $56.66 -0.45 (-0.79%) (As of 04:16 PM ET) Add Compare Share Share Today's Range$56.32▼$59.6650-Day Range$39.81▼$59.9952-Week Range$19.81▼$61.61Volume926,741 shsAverage Volume792,613 shsMarket Capitalization$3.33 billionP/E RatioN/ADividend YieldN/APrice Target$72.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Merus alerts: Email Address Merus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside26.6% Upside$72.70 Price TargetShort InterestBearish8.03% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 15 Articles This WeekInsider TradingSelling Shares$317,340 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.12) to ($3.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.52 out of 5 starsMedical Sector411th out of 905 stocksPharmaceutical Preparations Industry190th out of 425 stocks 4.5 Analyst's Opinion Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMerus has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Merus' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.03% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Merus has recently increased by 35.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRUS. Previous Next 3.0 News and Social Media Coverage News SentimentMerus has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Merus this week, compared to 3 articles on an average week.Search Interest17 people have searched for MRUS on MarketBeat in the last 30 days. This is an increase of 750% compared to the previous 30 days.MarketBeat Follows11 people have added Merus to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $317,340.00 in company stock.Percentage Held by InsidersOnly 4.57% of the stock of Merus is held by insiders.Percentage Held by Institutions96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Merus' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($3.12) to ($3.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -20.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -20.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 9.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Merus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted the 2008 housing crisis and the 2022 sell-off… Now, he says that despite the bull market, he's worried older Americans are holding the WRONG stocks in their portfolios for this stage of their lives. So, he's urging folks to buy "America's No. 1 Legacy Stock," which could help them build wealth they could pass on for generations.Learn more here. About Merus Stock (NASDAQ:MRUS)Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Read More MRUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRUS Stock News HeadlinesJune 7, 2024 | insidertrades.comMerus (NASDAQ:MRUS) VP Sells $317,340.00 in StockJune 11 at 1:36 AM | americanbankingnews.comMerus (NASDAQ:MRUS) Given Consensus Rating of "Buy" by AnalystsJune 7, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) VP Harry Shuman Sells 6,000 SharesJune 7, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Shares Down 2.2% on Analyst DowngradeJune 6, 2024 | americanbankingnews.comBMO Capital Markets Increases Merus (NASDAQ:MRUS) Price Target to $91.00June 6, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) PT Raised to $88.00June 6, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Stock Price Down 2.2% on Analyst DowngradeJune 5, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Given New $76.00 Price Target at Bank of AmericaJune 5, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Price Target Increased to $67.00 by Analysts at Canaccord Genuity GroupJune 3, 2024 | globenewswire.comMerus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual MeetingJune 3, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Expected to Post FY2027 Earnings of $4.93 Per ShareJune 2, 2024 | globenewswire.comMerus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual MeetingMay 29, 2024 | globenewswire.comMerus Announces Pricing of Upsized Public Offering of Common SharesMay 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Merus with Increased Price Objective Amid Promising Peto’ Efficacy and Market PotentialMay 29, 2024 | finance.yahoo.comThese Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under ThreatMay 29, 2024 | globenewswire.comMerus to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceMay 28, 2024 | globenewswire.comMerus N.V. Announces Proposed Public Offering of Common SharesMay 28, 2024 | finance.yahoo.comMerus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCCMay 28, 2024 | globenewswire.comMerus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCCMay 24, 2024 | barrons.comMerus Clears Wall Street's Bar With Cancer DataMay 24, 2024 | seekingalpha.comMerus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)May 24, 2024 | finance.yahoo.comWhy Is Cancer-Focused Merus Stock Trading Over 30% On Friday?May 24, 2024 | msn.comMerus rallies on publication of oncology study abstractsMay 24, 2024 | markets.businessinsider.comMerus’s Petosemtamab Shows Promising Trial Results, Analyst Recommends Buy with $54 Price TargetMay 24, 2024 | investors.comWhy Top 4% Biotech Stock, Merus, Just Catapulted To A Record HighSee More Headlines Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/12/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRUS CUSIPN/A CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees172Year FoundedN/APrice Target and Rating Average Stock Price Target$72.70 High Stock Price Target$93.00 Low Stock Price Target$45.00 Potential Upside/Downside+24.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,940,000.00 Net Margins-390.36% Pretax Margin-377.98% Return on Equity-44.13% Return on Assets-33.08% Debt Debt-to-Equity RatioN/A Current Ratio5.23 Quick Ratio5.23 Sales & Book Value Annual Sales$43.95 million Price / Sales78.13 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book9.48Miscellaneous Outstanding Shares58,690,000Free Float56,006,000Market Cap$3.43 billion OptionableOptionable Beta1.10 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Sven Ante Lundberg M.D. (Age 61)CEO, President & Executive Director Comp: $953.06kMr. Gregory D. Perry (Age 64)Chief Financial Officer Comp: $63.76kMr. Peter B. Silverman J.D. (Age 46)EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal Comp: $601.19kDr. Hui Liu Ph.D. (Age 57)Chief Business Officer, Executive VP & Head of Merus U.S. Comp: $597.7kDr. Andrew Joe M.D. (Age 57)Chief Medical Officer & Senior VP Comp: $692.74kDr. Hennie HoogenboomCo-Founder and Scientific AdvisorHarry ShumanChief Accounting OfficerMr. Cornelis Adriaan de Kruif Ph.D. (Age 59)CTO & Executive VP Comp: $350.85kDr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Senior VPKathleen FarrenIR & Corporate Communications OfficerMore ExecutivesKey CompetitorsViatrisNASDAQ:VTRSUnited TherapeuticsNASDAQ:UTHRDr. Reddy's LaboratoriesNYSE:RDYSarepta TherapeuticsNASDAQ:SRPTCatalentNYSE:CTLTView All CompetitorsInsiders & InstitutionsHarry ShumanSold 6,000 sharesTotal: $317,340.00 ($52.89/share)Lynx1 Capital Management LPBought 373,782 shares on 5/30/2024Ownership: 2.571%Virtu Financial LLCBought 12,321 shares on 5/20/2024Ownership: 0.021%Artal Group S.A.Bought 455,081 shares on 5/17/2024Ownership: 0.775%Janus Henderson Group PLCBought 11,536 shares on 5/16/2024Ownership: 0.924%View All Insider TransactionsView All Institutional Transactions MRUS Stock Analysis - Frequently Asked Questions Should I buy or sell Merus stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRUS shares. View MRUS analyst ratings or view top-rated stocks. What is Merus' stock price target for 2024? 12 Wall Street research analysts have issued 1-year price objectives for Merus' shares. Their MRUS share price targets range from $45.00 to $93.00. On average, they predict the company's stock price to reach $72.70 in the next twelve months. This suggests a possible upside of 26.6% from the stock's current price. View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts. How have MRUS shares performed in 2024? Merus' stock was trading at $27.50 at the start of the year. Since then, MRUS stock has increased by 108.9% and is now trading at $57.44. View the best growth stocks for 2024 here. Are investors shorting Merus? Merus saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 4,710,000 shares, an increase of 35.3% from the May 15th total of 3,480,000 shares. Based on an average trading volume of 933,300 shares, the short-interest ratio is currently 5.0 days. View Merus' Short Interest. When is Merus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our MRUS earnings forecast. How were Merus' earnings last quarter? Merus (NASDAQ:MRUS) announced its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.24. The biotechnology company had revenue of $7.89 million for the quarter, compared to analysts' expectations of $8.94 million. Merus had a negative net margin of 390.36% and a negative trailing twelve-month return on equity of 44.13%. What ETFs hold Merus' stock? ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Range Cancer Therapeutics ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Loncar China Biopharma ETF (CHNA), Tema Oncology ETF (CANC), BlackRock Future Health ETF (BMED) and Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC). When did Merus IPO? Merus (MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. Who are Merus' major shareholders? Merus' stock is owned by a number of institutional and retail investors. Top institutional investors include Lynx1 Capital Management LP (2.57%), Price T Rowe Associates Inc. MD (2.02%), BVF Inc. IL (2.00%), Medicxi Ventures Management Jersey Ltd (1.99%), Janus Henderson Group PLC (0.92%) and Artal Group S.A. (0.78%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRUS) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | Sponsored$9 AI Model with 90% Win Rate?What if I told you it could take just $9… To win 90% of your options trades?Trade Machine | SponsoredThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $...Stansberry Research | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.